Davide Melisi - Researcher Profile | RDL Research Database

Publications

2 shown

Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells

Roberto Bianco , Roberta Rosa , Vincenzo Damiano +11 more

Abstract Purpose: The resistance to selective EGFR inhibitors involves the activation of alternative signaling pathways, and Akt activation and VEGF induction have been describe...

2008 Clinical Cancer Research 143 citations

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa , Vaibhav Sahai , Antoine Hollebecque +16 more

Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, ...

2020 The Lancet Oncology 1455 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 1,598
Institution: University of Naples Federico II

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-4031-7585

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.